ANVSNYSEPharmaceutical PreparationsFiscal year ends December 31
Annovis Bio, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026
$0.96−0.03 (-3.36%)
Close on Oct 19, 2026
- Market cap
- $36.02M
- P/E (TTM)
- –
- Dividend yield
- –
Share price
−$1.0200 (−51.52%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
Annovis Bio, Inc. reported revenue of $0 for the twelve months to Jun 30, 2026.
Revenue
$0
TTM Q2 2026
Operating income
-$49.53M
TTM Q2 2026
EPS, diluted
-$1.78
TTM Q2 2026
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $36.02M
- P/E ratio
- –
- Price to sales
- –
- Price to book
- –
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Revenue
- $0
- Net income
- -$49.52M
- EPS, diluted
- -$1.78
- Book value per share
- -$0.11
- Diluted shares
- 38M
Eight years at a glance
Fiscal years 2018 to 2025 and trailing twelve months, USD
Revenue
$0
Operating income
-$49.53M
Net income
-$49.52M
EPS, diluted
-$1.78
Reported periodTrailing twelve months